HIPRA

HIPRA is a biotech pharmaceutical company headquartered in Amer, Catalonia, Spain focused on prevention for animal and human health, with a product base of vaccines and a diagnostic service.

HIPRA has a international presence in more than 40 countries with its own subsidiaries, 3 R&D centres and production plants located in Europe (Spain) and America (Brazil).

In addition, its international distribution network maintains open distribution channels with more than 100 countries, covering all 5 continents.[1]

Since 2020, the company has been developing a vaccine against COVID-19.[2]

History

The beginnings date back to 1971 when a group of young entrepreneurs acquired a small laboratory in Madrid founded in 1954, called HIPRA (by the surnames of its former creators: Hidalgo and Prada), and moved to Amer (Girona).[3]

During 1991, with a workforce of 100 people and a turnover of 10 million euros, was a crucial year in HIPRA's history. A new management team redefines the company's expansion policy.

As of 2000, the company began the internationalization of HIPRA with the implementation of its own subsidiaries around the world.[3] Currently HIPRA has commercial subsidiaries in 40 countries, 3 research centers and 6 production plants located in Europe and America. Its distribution network covers the 5 continents.

In 2009 the positioning was refined to focus on prevention, with different and products and, therefore, it stopped investing in pharmacological products.[3]

In 2020, and in a context of the Covid-19 pandemic, a new challenge was faced using its experience in vaccines, the development of the vaccine against this new virus based on recombinant protein.[4]

In 2021 the new Human Health division was created to develop new products.[5] The same year GoodGut was acquired, a biotechnological start-up dedicated to the research and development of diagnostic tests for digestive diseases.[6]

Animal health

HIPRA has developed more than 100 vaccines for different animal species, both production and companion animals, against a wide variety of biological targets. In addition to its Amer plant, the company has another plant in Brazil, in the Porto Alegre conurbation. It also has a university research centre in the United States.[7]

HIPRA's animal health products include vaccines, vaccination devices,[8] integrated traceability services and diagnostic kits.

References
  1. "Hipra". Parc Científic de Barcelona. 2020-10-20. Retrieved 2022-11-14.
  2. Limón, Raúl (2021-08-12). "First Spanish Covid-19 vaccine approved for human clinical trial". EL PAÍS English Edition. Retrieved 2021-11-05.
  3. "La vacuna de Hipra crea más anticuerpos que la de Pfizer como dosis de refuerzo". La Vanguardia (in Spanish). 2022-03-15. Retrieved 2022-11-15.
  4. EFE, Agencia (2022-02-01). "Hipra, de la salud animal a una vacuna competitiva y con pocas reacciones". COPE (in Spanish). Retrieved 2022-11-15.
  5. rumiNews (2020-12-14). "HIPRA da un paso firme hacia la salud humana con la vacuna frente a la Covid-19". Rumiantes el portal de rumiNews. Retrieved 2022-11-15.
  6. Bosch, Imma. "Hipra compra l'empresa Goodgut - 19 ago 2021". El Punt Avui (in Catalan). Retrieved 2022-11-15.
  7. "La vacuna de Hipra crea más anticuerpos que la de Pfizer como dosis de refuerzo". La Vanguardia (in Spanish). 2022-03-15. Retrieved 2022-11-18.
  8. Beek, Vincent ter (2016-06-24). "Hipra takes one step forward in Smart Vaccination". Pig Progress. Retrieved 2022-11-18.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.